Controversies in antiplatelet therapy for patients with cardiovascular disease.
Bates
Eric R
ER
Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Mich, USA. ebates@umich.edu
Lau
Wei C
WC
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004347:Drug Interactions; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006538:Heptanoic Acids / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011758:Pyrroles / Q000493:pharmacokinetics / Q000494:pharmacology
D000806:Angiotensin-Converting Enzyme Inhibitors; D016861:Cyclooxygenase Inhibitors; D006538:Heptanoic Acids; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D001241:Aspirin